Establishment of a Sensitive Monoclonal Antibody Against Mouse CCR9 (C9Mab-24) for Flow Cytometry [0.03%]
用于流式细胞术的高灵敏度小鼠CCR9单克隆抗体(C9Mab-24)的建立
Hiyori Kobayashi,Teizo Asano,Hiroyuki Suzuki et al.
Hiyori Kobayashi et al.
The CC chemokine receptor 9 (CCR9), also known as CD199, is one of chemokine receptors. The CC chemokine ligand 25 (CCL25) is known to be the only ligand for CCR9. The CCR9-CCL25 interaction plays important roles in chemotaxis of lymphocyte...
Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma [0.03%]
去岩藻糖鼠犬嵌合抗人表皮生长因子受体2单克隆抗体(H77Bf)对犬骨肉瘤小鼠异种移植模型的抗肿瘤作用
Ren Nanamiya,Tomokazu Ohishi,Hiroyuki Suzuki et al.
Ren Nanamiya et al.
Human epidermal growth factor receptor 2 (HER2) has been studied in many human cancer types, and its overexpression and/or gene mutation contribute to the poor prognosis. Therefore, HER2 is an important therapeutic target in various cancer ...
Epitope Mapping Using the Cell-Based 2 × Alanine Substitution Method About the Anti-mouse CXCR6 Monoclonal Antibody, Cx6Mab-1 [0.03%]
使用基于细胞的2×丙氨酸替代方法对抗小鼠CXCR6单克隆抗体Cx6Mab-1进行表位定位研究
Yu Isoda,Tomohiro Tanaka,Hiroyuki Suzuki et al.
Yu Isoda et al.
An anti-mouse CXC chemokine receptor 6 (mCXCR6) monoclonal antibody (mAb), Cx6Mab-1, was developed recently. Cx6Mab-1 is applicable for flow cytometry, Western blotting, and enzyme-linked immunosorbent assay. The purpose of this study is to...
Development of a Novel Anti-Mouse CCR6 Monoclonal Antibody (C6Mab-13) by N-Terminal Peptide Immunization [0.03%]
通过N端肽免疫开发新型抗小鼠CCR6单克隆抗体(C6Mab-13)
Teizo Asano,Tomohiro Tanaka,Hiroyuki Suzuki et al.
Teizo Asano et al.
The CC chemokine receptor 6 (CCR6) is a G protein-coupled receptor family member that is highly expressed in B lymphocytes, certain subsets of effector and memory T cells, and immature dendritic cells. CCR6 has only one chemokine ligand, CC...
Development of a Sensitive Anti-Human CCR9 Monoclonal Antibody (C9Mab-11) by N-Terminal Peptide Immunization [0.03%]
通过N端肽免疫开发一种敏感的抗人CCR9单克隆抗体(C9Mab-11)
Tomohiro Tanaka,Hiroyuki Suzuki,Yu Isoda et al.
Tomohiro Tanaka et al.
The C-C chemokine receptor 9 (CCR9) belongs to the G-protein-coupled receptor superfamily, and is highly expressed on the T cells and intestinal cells. CCR9 regulates various immune responses by binding to the C-C chemokine ligand, CCL25, a...
Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf) [0.03%]
犬抗HER2单克隆抗体(H77Bf)对犬成纤维肿瘤的抗肿瘤活性研究
Hiroyuki Suzuki,Teizo Asano,Tomokazu Ohishi et al.
Hiroyuki Suzuki et al.
Human epidermal growth factor receptor 2 (HER2) is a cell surface type I transmembrane glycoprotein that is overexpressed on a variety of solid tumors and transduces the oncogenic signaling upon homo- and heterodimerization with HER familie...
Epitope Mapping of an Anti-Mouse CCR2 Monoclonal Antibody (C2Mab-6) Using Enzyme-Linked Immunosorbent Assay [0.03%]
使用酶联免疫吸附试验对反鼠CCR2单克隆抗体(C2Mab-6)的表位进行测定
Tomohiro Tanaka,Hiroyuki Suzuki,Teizo Asano et al.
Tomohiro Tanaka et al.
CC chemokine receptor type-2 (CCR2) is a member of the G protein-coupled receptors, and is mainly expressed on cell surface of immune cells. CCR2 binds to its ligand, C-C motif chemokine 2 (also named as monocyte chemoattractant protein-1),...
National Control Laboratory Assessment of Quality of Rituximab Biosimilars in India [0.03%]
印度全国控制实验室关于利妥昔单抗生物类似药质量的评估
Nripendra Nath Mishra,Anu Sharma,Swati Shalini et al.
Nripendra Nath Mishra et al.
In past few years many rituximab (RTX) biosimilars have been launched in India. Biosimilars are products that are similar in terms of quality, safety, and efficacy to its innovator product and are expected to offer improved affordability. T...
Broad Based Immunity? [0.03%]
广泛的免疫作用？
Thomas Kieber-Emmons
Thomas Kieber-Emmons
Anastas Pashov,Ramachandran Murali,Issam Makhoul et al.
Anastas Pashov et al.
Targeting the diverse glycan repertoire expressed on tumor cells is considered a viable therapeutic strategy to deal with tumor cell heterogeneity. Inherently polyspecific, natural, glycan-reactive antibodies are purported to be protective ...